bivalent Lm-LLO immunotherapies (Advaxis)

N/A

Report date: 2025/03/14 16:39:52
NME

Base Information

Drug Namebivalent Lm-LLO immunotherapies (Advaxis)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCarbonic anhydrase IX modulatorsMelanoma-specific antigens modulatorsReceptor tyrosine-protein kinase erbB-3 modulators
TargetsCarbonic anhydrase IXMelanoma-specific antigensReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAyala Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAyala Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A